From tea towels to TV remotes: eight everyday bacterial hotspots – and how to clean them
But here's the catch: some of the dirtiest items in your life are the ones you might least expect.
Here are some of the hidden bacteria magnets in your daily routine, and how simple hygiene tweaks can protect you from infection.
Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences.
Shopping trolley handles
Shopping trolleys are handled by dozens of people each day, yet they're rarely sanitised. That makes the handles a prime spot for germs, particularly the kind that spread illness.
One study in the US found that over 70% of shopping carts were contaminated with coliform bacteria, a group that includes strains like E. coli, often linked to faecal contamination. Another study found Klebsiella pneumoniae, Citrobacter freundii and Pseudomonas species on trolleys.
Protect yourself: Always sanitise trolley handles before use, especially since you'll probably be handling food, your phone or touching your face.
Kitchen sponges
That sponge by your sink? It could be one of the dirtiest items in your home. Sponges are porous, damp and often come into contact with food: ideal conditions for bacteria to thrive.
After just two weeks, a sponge can harbour millions of bacteria, including coliforms linked to faecal contamination, according to the NSF Household Germ Study and research on faecal coliforms.
Protect yourself: Disinfect your sponge weekly by microwaving it, soaking it in vinegar, or running it through the dishwasher. Replace it if it smells – even after cleaning. Use different sponges for different tasks (for example, one for dishes, another for cleaning up after raw meat).
Chopping boards
Chopping boards can trap bacteria in grooves left by knife cuts. Salmonella and E. coli can survive for hours on dry surfaces and pose a risk if boards aren't cleaned properly.
Protect yourself: Use separate boards for raw meat and vegetables. Wash thoroughly with hot, soapy water, rinse well and dry completely. Replace boards that develop deep grooves.
Tea towels
Reusable kitchen towels quickly become germ magnets. You use them to dry hands, wipe surfaces and clean up spills – often without washing them often enough.
Research shows that E. coli and salmonella can live on cloth towels for hours.
Protect yourself: Use paper towels when possible, or separate cloth towels for different jobs. Wash towels regularly in hot water with bleach or disinfectant.
Mobile phones
Phones go everywhere with us – including bathrooms – and we touch them constantly. Their warmth and frequent handling make them ideal for bacterial contamination.
Research shows phones can carry harmful bacteria, including Staphylococcus aureus.
Protect yourself: Avoid using your phone in bathrooms and wash your hands often. Clean it with a slightly damp microfibre cloth and mild soap. Avoid harsh chemicals or direct sprays.
Toothbrushes near toilets
Flushing a toilet releases a plume of microscopic droplets, which can land on nearby toothbrushes. A study found that toothbrushes stored in bathrooms can harbour E. coli, Staphylococcus aureus and other microbes.
Read more:
Protect yourself: Store your toothbrush as far from the toilet as possible. Rinse it after each use, let it air-dry upright and replace it every three months – or sooner if worn.
Bathmats
Cloth bathmats absorb water after every shower, creating a warm, damp environment where bacteria and fungi can thrive.
Protect yourself: Hang your bathmat to dry after each use and wash it weekly in hot water. For a more hygienic option, consider switching to a wooden mat or a bath stone: a mat made from diatomaceous earth, which dries quickly and reduces microbial growth by eliminating lingering moisture.
Pet towels and toys
Pet towels and toys stay damp and come into contact with saliva, fur, urine and outdoor bacteria. According to the US national public health agency, the Centers for Disease Control and Prevention, pet toys can harbour E. coli, Staphylococcus aureus and Pseudomonas aeruginosa.
Protect your pet (and yourself): Wash pet towels weekly with hot water and pet-safe detergent. Let toys air dry or use a dryer. Replace worn or damaged toys regularly.
Shared nail and beauty tools
Nail clippers, cuticle pushers and other grooming tools can spread harmful bacteria if they're not properly cleaned. Contaminants may include Staphylococcus aureus – including MRSA, a strain resistant to antibiotics – Pseudomonas aeruginosa, the bacteria behind green nail syndrome, and Mycobacterium fortuitum, linked to skin infections from pedicures and footbaths.
Protect yourself: Bring your own tools to salons or ask how theirs are sterilised. Reputable salons will gladly explain their hygiene practices.
Airport security trays
Airport trays are handled by hundreds of people daily – and rarely cleaned. Research has found high levels of bacteria, including E. coli.
Protect yourself: After security, wash your hands or use sanitiser, especially before eating or touching your face.
Hotel TV remotes
Studies show hotel remote controls can be dirtier than toilet seats. They're touched by many hands and rarely sanitised.
Common bacteria include E. coli, enterococcus and Staphylococcus aureus, including MRSA, according to research.
Protect yourself: Wipe the remote with antibacterial wipes when you arrive. Some travellers even put it in a plastic bag. Always wash your hands after using shared items.
Bacteria are everywhere, including on the items you use every day. You can't avoid all germs, and most won't make you sick. But with a few good habits, such as regular hand washing, cleaning and smart storage, you can help protect yourself and others.
It's all in your hands.
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Manal Mohammed does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Akari Therapeutics Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
Video webcast now available on-demand BOSTON and LONDON, July 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced Abizer Gaslightwala, Director, President and Chief Executive Officer of Akari, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. As part of the event, Mr. Gaslightwala dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development. The on-demand video webcast is now available on as well as the Presentations page in the Investors section of the Company's website ( About Akari Therapeutics Akari Therapeutics is an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs). The Company has developed its first novel payload, PH1, a spliceosome inhibitor designed to disrupt RNA splicing within cells. PH1 is highly differentiated in its mechanism of action against cancer cells from current ADC payloads that use Topoisomerase1 inhibitors or tubulin inhibitors. This splicing inhibition has been shown in preclinical animal models to induce cancer cell death while activating immune cells to drive robust and durable activity. Using this novel payload, Akari has the ability to generate multiple ADC molecules based on the desired application to a range of cancer targets of interest. Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers its novel PH1 payload directly into the tumor. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival, relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors, as compared to appropriate controls. The Company is generating validating data on its novel payload PH1 to continue advancing its lead asset, as well as other undisclosed targets with this novel payload. For more information about the Company, please visit and connect on X and LinkedIn. Investor Relations Contact JTC Team, LLC Jenene Thomas 908-824-0775 AKTX@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Forbes
19 minutes ago
- Forbes
Can A Chatbot Be Your Therapist? Casper's Neil Parikh Launches A New $93 Million Startup To Try
Daniel Cahn (left) and Neil Parikh (right), cofounders of Slingshot AI. courtesy of slingshot N eil Parikh's first startup Casper made sleep easy—and even cool. The med school dropout used tech to help people buy mattresses with just a few clicks. Now he wants to make getting therapy just as simple. After turning the sleep brand into a billion-dollar business, the Forbes Under 30 alum is back with a new venture: Slingshot AI, a startup building a chatbot designed to replicate the experience of talking to a therapist. 'I never really thought about therapy,' Parikh told Forbes . 'Then I found a therapist who changed my life.' That's how it clicked for the entrepreneur. While millions struggle with mental health issues, access to care is staggeringly limited. 'We realized there's over 10,000 people who want care for every therapist that's out there,' he said. 'There was an opportunity for AI to actually help people in a new way.' On Tuesday, Slingshot officially launched its AI-powered therapy bot, called Ash, and announced a follow-on Series A round co-led by Radical Ventures and Forerunner Ventures, with participation from existing investors Andreessen Horowitz, Menlo Ventures and others. The round brings Slingshot's total funding to $93 million as it emerges from beta after being tested with more than 50,000 users. Parikh founded the startup with Daniel Cahn, a machine learning engineer who previously worked on AI tools for mental health in the UK. Unlike general purpose models like ChatGPT—which pull data from the internet—Ash was developed in collaboration with clinicians and trained specifically on behavioral health data. It doesn't offer advice or try to diagnose, but is instead designed to guide users more through self-reflection, similar to how a therapist might prompt deeper thinking. Andreessen Horowitz's a16z was quick to back the entrepreneur. Daisy Wolf, partner at the firm, said they'd been actively looking for a startup bringing AI into the mental health space, handing Slingshot a term sheet as soon as the team was ready to raise. 'They have the experience and know how to pull this off. They've been absolute magnets for talent, and the caliber of people they've been able to recruit has continued to blow us away,' Wolf said. Parikh was 22 when he dropped out of medical school to build Casper. The company wasn't the first to sell mattresses online, but it was the first to become a household name with mattress-in-a-box convenience and a wellness-focused message that turned sleep into a lifestyle. Celebrity endorsements and subway ads helped build the brand amongst a younger audience. Parikh went all in and even co-authored a book on sleep. Casper went public in 2020 at $12 a share—below its target range—and returned to private ownership two years later. He stepped down in 2021 and fully exited the board after the sale. Since then, he's invested in more than 150 startups, many tied to mental health. Now back in the founder seat, he says building from the ground up is both daunting and exciting. 'Every part of this business is really challenging when you think about it. You have to build a large scale data set through partnerships. You have to build a team that knows how to train AI models. You actually have to learn how to train the models,' he said. The burning question: Can a chatbot really compare to a human therapist? Though the concept of AI therapy might seem experimental, early evidence suggests it could have real potential. At Dartmouth College, researchers developed and tested their own chatbot therapist called Therabot. In a trial of more than 100 people with mental health conditions, all improved. Those with depression saw a 51% symptom drop on average. Nicholas Jacobson, one of the clinicians behind Therabot, said chatbots can offer several advantages over traditional care, including cost, convenience and 24/7 availability. Even individuals who had not previously responded to therapy saw significant improvement with Therabot. "A full caseload is about 26-and-a-half patients a week for a practicing therapist,' he said. 'They will see their patients generally once a week in outpatient settings for about 45 minutes.' In that case, why not use the widely popular generative AI models like ChatGPT or Google's Gemini? While these models are incredibly advanced, they aren't designed specifically for mental health care, Jacobson said, and can be potentially harmful. At Dartmouth, this meant researchers had to build their own data from scratch. At Slingshot, it means partnering directly with clinicians—and using that $93 million to build a better data pipeline. And, Parikh adds, general models can be somewhat of yes-men. 'You want them to appropriately push back on you. That's a core part of self growth.' Courtesy of Slingshot Still, not everyone is convinced chatbots can handle mental health responsibly. Critics have raised concerns about safety and privacy. Slingshot says it's proactively addressing these issues by working with a clinical advisory board. Ash, for example, redirects users experiencing a serious crisis to human professionals. This time around, the serial entrepreneur (who's gone to plenty of therapy since) wants to keep the company lean and mission-driven. For its initial launch, Ash will be available for free to users, and Parikh imagines rolling out a subscription model priced similarly to Netflix. In the future, there may be avenues for Ash to be available via employers or insurance. In the meantime, Parikh says he isn't trying to reinvent therapy, but hoping Ash might just help more people start it. 'Doing anything that nobody's done before means that you have to figure out a lot of new things,' he said. 'It's a lot of unknown nodes, but it's also cool because every day we get to wake up and get feedback from people who say this is incredible and their lives changed.'


Bloomberg
19 minutes ago
- Bloomberg
FDA Rejects Replimune's Skin Cancer Treatment, Shares Sink
US regulators rejected a skin cancer treatment from Replimune Group Inc. in another sign of the agency's new leadership taking a hard line on drug approvals. The US Food and Drug Administration denied the company's application to treat advanced melanoma with a combination of its immunotherapy and another cancer drug.